The Panuveitis drugs in development market research report provides comprehensive information on the therapeutics under development for Panuveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Panuveitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Panuveitis and features dormant and discontinued products.
GlobalData tracks five drugs in development for Panuveitis by five companies/universities/institutes. The top development phase for Panuveitis is preclinical with one drugs in that stage. The Panuveitis pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Panuveitis pipeline products market are: Revolo Biotherapeutics, Nordic Group and BioNanoSim.
The key targets in the Panuveitis pipeline products market include Interleukin 17A, Calcineurin, and Endoplasmic Reticulum Chaperone BiP.
The key mechanisms of action in the Panuveitis pipeline product include Calcineurin Inhibitor with one drug in Preclinical. The Panuveitis pipeline products include six routes of administration with the top ROA being Oral and three key molecule types in the Panuveitis pipeline products market including Small Molecule, and Fusion Protein.
Panuveitis overview
Panuveitis, or diffuse uveitis, is the inflammation of uveal components of the eye. It is caused by inflammation due to infections, immune-related inflammation, intraocular malignancies like retinoblastoma or iris melanoma, and traumas. Symptoms include pain, redness, watery discharge, photophobia, and edema. Diagnostics tests include blood tests, X-ray, and thorough eye examination, which includes slit-lamp exam, tonometry, and dilated eye exam. The treatment varies depending on causative agent. Nonspecific treatment includes cycloplegics, systemic immunosuppressants, biological agents, and corticosteroids.
For a complete picture of Panuveitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
